These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 22337948)
1. HCV genotype-3a T cell immunity: specificity, function and impact of therapy. Humphreys IS; von Delft A; Brown A; Hibbert L; Collier JD; Foster GR; Rahman M; Christian A; Klenerman P; Barnes E Gut; 2012 Nov; 61(11):1589-99. PubMed ID: 22337948 [TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Cramp ME; Rossol S; Chokshi S; Carucci P; Williams R; Naoumov NV Gastroenterology; 2000 Feb; 118(2):346-55. PubMed ID: 10648463 [TBL] [Abstract][Full Text] [Related]
3. Concomitant augmentation of type 1 CD4+ and CD8+ T-cell responses during successful interferon-alpha and ribavirin treatment for chronic hepatitis C virus infection. Sreenarasimhaiah J; Jaramillo A; Crippin J; Lisker-Melman M; Chapman WC; Mohanakumar T Hum Immunol; 2003 May; 64(5):497-504. PubMed ID: 12691700 [TBL] [Abstract][Full Text] [Related]
4. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C. Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692 [TBL] [Abstract][Full Text] [Related]
5. Clinical responders to antiviral therapy of chronic HCV infection show elevated antiviral CD4+ and CD8+ T-cell responses. Pillai V; Lee WM; Thiele DL; Karandikar NJ J Viral Hepat; 2007 May; 14(5):318-29. PubMed ID: 17439521 [TBL] [Abstract][Full Text] [Related]
6. Could a loss of memory T cells limit responses to hepatitis C virus (HCV) antigens in blood leucocytes from patients chronically infected with HCV before and during pegylated interferon-alpha and ribavirin therapy? Lee S; Hammond T; Watson MW; Flexman JP; Cheng W; Fernandez S; Price P Clin Exp Immunol; 2010 Jul; 161(1):118-26. PubMed ID: 20408862 [TBL] [Abstract][Full Text] [Related]
7. The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design. von Delft A; Humphreys IS; Brown A; Pfafferott K; Lucas M; Klenerman P; Lauer GM; Cox AL; Gaudieri S; Barnes E Gut; 2016 Jan; 65(1):112-23. PubMed ID: 26092843 [TBL] [Abstract][Full Text] [Related]
9. Naturally occurring resistance mutations within the core and NS5B regions in hepatitis C genotypes, particularly genotype 5a, in South Africa. Prabdial-Sing N; Blackard JT; Puren AJ; Mahomed A; Abuelhassan W; Mahlangu J; Vermeulen M; Bowyer SM Antiviral Res; 2016 Mar; 127():90-8. PubMed ID: 26704023 [TBL] [Abstract][Full Text] [Related]
10. Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses. Aregay A; Owusu Sekyere S; Deterding K; Port K; Dietz J; Berkowski C; Sarrazin C; Manns MP; Cornberg M; Wedemeyer H J Hepatol; 2019 Nov; 71(5):889-899. PubMed ID: 31295532 [TBL] [Abstract][Full Text] [Related]
11. CD4 T lymphocyte proliferative responses to hepatitis C virus (HCV) antigens in patients coinfected with HCV and human immunodeficiency virus who responded to anti-HCV treatment. Legrand E; Neau D; Galperine T; Trimoulet P; Moreau JF; Pitard V; Lacut JY; Ragnaud JM; Dupon M; Le Bail B; Bernard N; Schvoerer E; Houghton M; Fleury H; Lafon ME J Infect Dis; 2002 Aug; 186(3):302-11. PubMed ID: 12134226 [TBL] [Abstract][Full Text] [Related]
12. Strain-specific T-cell suppression and protective immunity in patients with chronic hepatitis C virus infection. Sugimoto K; Kaplan DE; Ikeda F; Ding J; Schwartz J; Nunes FA; Alter HJ; Chang KM J Virol; 2005 Jun; 79(11):6976-83. PubMed ID: 15890937 [TBL] [Abstract][Full Text] [Related]
13. Evidence of CD4 Lucas M; Deshpande P; James I; Rauch A; Pfafferott K; Gaylard E; Merani S; Plauzolles A; Lucas A; McDonnell W; Kalams S; Pilkinton M; Chastain C; Barnett L; Prosser A; Mallal S; Fitzmaurice K; Drummer H; Ansari MA; Pedergnana V; Barnes E; John M; Kelleher D; Klenerman P; Gaudieri S Sci Rep; 2018 May; 8(1):7224. PubMed ID: 29740042 [TBL] [Abstract][Full Text] [Related]
14. HCV-specific immune responses induced by CIGB-230 in combination with IFN-α plus ribavirin. Amador-Cañizares Y; Martínez-Donato G; Alvarez-Lajonchere L; Vasallo C; Dausá M; Aguilar-Noriega D; Valenzuela C; Raíces I; Dubuisson J; Wychowski C; Cinza-Estévez Z; Castellanos M; Núñez M; Armas A; González Y; Revé I; Guerra I; Pérez Aguiar A; Dueñas-Carrera S World J Gastroenterol; 2014 Jan; 20(1):148-62. PubMed ID: 24415868 [TBL] [Abstract][Full Text] [Related]
15. Direct evidence for immunomodulatory properties of ribavirin on T-cell reactivity to hepatitis C virus. Rigopoulou EI; Abbott WG; Williams R; Naoumov NV Antiviral Res; 2007 Jul; 75(1):36-42. PubMed ID: 17210188 [TBL] [Abstract][Full Text] [Related]